Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Is Novo Nordisk (CPSE:NOVO B) Cheap After Lillys EMA Win Raised GLP 1 Pressure?

Company update AI-generated analysis

📉 Novo Nordisk shares have fallen 21.39% year-to-date and 20.63% over one year amid intensified GLP-1 competition from Eli Lilly's newly approved Foundayo.

💰 The company maintains a robust economic moat through decades of diabetes expertise, trusted global branding, and advanced manufacturing capabilities.

📈 Strong historical performance is evidenced by 20.8% annual earnings growth over the past five years and consistent net profit margins around 35.3%.

🏭 Management is strategically reinvesting massive capital inflows from its obesity franchise into manufacturing and new therapies to sustain long-term leadership.

💵 Valuation metrics show Novo Nordisk trading at a P/E of 9.9x, significantly below the European pharmaceutical peer average of 19.6x.

🔮 Analyst forecasts project essentially flat earnings growth over the next three years with revenue expansion slowing to 3.2% annually.

⚖️ Simply Wall St analysis calculates a fair value of DKK851, implying the current share price is approximately 69% undervalued.

🛡️ The company has successfully transformed into a highly profitable obesity treatment business segment built on its existing scientific platform.

⚠️ Key risks include potential pricing pressure in major markets and execution challenges in scaling manufacturing capacity against rivals.

📊 Return on equity remains outstanding at 52.6%, highlighting the efficiency of capital deployment within the current business structure.

Bullish Signals
  • Novo Nordisk possesses a formidable economic moat built on decades of diabetes expertise, world-class manufacturing, and a trusted global brand.
  • The company has effectively gained a highly profitable new obesity business segment almost for free by leveraging its existing scientific platform.
  • Earnings have grown 20.8% per year over the past five years while maintaining net profit margins of 35.3%.
  • Return on equity sits at an outstanding 52.6%, demonstrating exceptional capital efficiency and profitability.
  • Management is wisely reinvesting massive capital inflows into manufacturing and new therapies to secure long-term leadership.
  • The stock trades at a P/E of 9.9x, which is significantly lower than the European pharmaceutical peer average of 19.6x.
Risk Factors
  • Novo Nordisk faces direct competitive pressure from Eli Lilly's Foundayo, which recently cleared a key EMA panel for obesity and type 2 diabetes.
  • Investors are weighing stronger GLP-1 competition and potential pricing pressure in the U.S. against pipeline hopes.
  • Forecasts point to essentially flat earnings over the next three years with a projected decline of 0.01% per year.
  • Revenue growth expectations of 3.2% per year trail both past performance and the wider Danish market average.
Full Analysis
Novo Nordisk (NVO) faces renewed competitive pressure following the European Medicines Agency's approval of Eli Lilly's Foundayo for obesity and type 2 diabetes. This development intensifies scrutiny on Novo's oral Wegovy pill within the crowded GLP-1 market, contributing to a significant share price decline. The stock has dropped 21.39% year-to-date and is down 20.63% over the last year as investors weigh competition against long-term franchise value. Despite the short-term volatility, Simply Wall St analysis suggests Novo Nordisk remains deeply undervalued at DKK259.6 compared to a calculated fair value of DKK851. The company boasts a formidable economic moat built on decades of diabetes expertise and world-class manufacturing capabilities. Its recent success in obesity has created a highly profitable new segment, driving massive capital inflows that management is reinvesting to secure long-term leadership. Fundamental metrics support the bullish thesis, with earnings growing 20.8% annually over the past five years and net profit margins holding steady at 35.3%. Return on equity stands at an outstanding 52.6%, while the current P/E ratio of 9.9x is significantly lower than European pharmaceutical peers averaging 19.6x. However, future outlooks indicate essentially flat earnings growth over the next three years and revenue expansion trailing past performance. The investment case hinges on two critical factors: managing pricing pressure in key markets and successfully ramping manufacturing capacity to compete with rivals like Eli Lilly. While forecasts suggest a slowdown in growth rates compared to historical performance, the market appears to be pricing in a temporary sentiment shift rather than a fundamental collapse of the business model.